pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 38 | Non-oncology: 26 Oncology: 12 |
| Under Consideration for Negotiation | 11 | Non-oncology: 5 Oncology: 6 |
| Completed Negotiations | 816 | With Letter of Intent: 707 Without agreement: 109 |
| Negotiations That Were Not Pursued | 110 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Osdenza | Apotex Inc. | Osteoporosis | |
| Symtuza | Janssen Inc. | HIV-1 Infection | |
| Bilprevda | Organon Canada Inc. | Multiple Indications | |
| Oslya | Mantra Pharma | Multiple Indications | |
| Bildyos | Organon Canada Inc. | Multiple Indications | |
| Idenos | Apotex Inc. | Multiple Indications | |
| Obodence | Samsung Bioepis Co., Ltd. | Multiple Indications | |
| Rystiggo | UCB Canada Inc. | Generalized myasthenia gravis (gMG) | |
| Imfinzi | AstraZeneca Canada Inc. | in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment | |
| Pemazyre | Incyte Biosciences Canada Corporation | For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement. | |
| Spevigo | Boehringer Ingelheim (Canada) Ltd. | generalized pustular psoriasis (GPP) |